Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 12/20 | 0.67 |
| ▸ | MAP3K9 | P80192 | 11/20 | 0.67 |
| ▸ | MAP3K10 | Q02779 | 7/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | DLK1 | P80370 | 1/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.64 |
| ▸ | PAK3 | O75914 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.53 |
| ▸ | PRKCG | P05129 | 2/20 | 0.53 |
| ▸ | PRKCB | P05771 | 2/20 | 0.53 |
| ▸ | PRKCA | P17252 | 2/20 | 0.53 |
| ▸ | PRKCH | P24723 | 2/20 | 0.53 |
| ▸ | PRKCI | P41743 | 2/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447166 | 0.87 | PRKCQ (0.71) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| SCHEMBL30309325 | 0.83 | PRKCQ (0.71) | MAP3K10FLT1FLT4KDRPRKCQ | |
| Cep-1347 SCHEMBL8263437 | 0.81 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| Cep-1347 SCHEMBL30198505 | 0.81 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| Cep-1347 SCHEMBL12047710 | 0.81 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| Cep-1347 SCHEMBL29381680 | 0.81 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| SCHEMBL5964631 | 0.80 | MAP3K11 (0.86) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| SCHEMBL14825401 | 0.80 | MAP3K11 (0.60) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| SCHEMBL8280372 | 0.79 | MAP3K11 (0.79) | MAP3K11MAP3K9MAP3K10FLT1FLT4 | |
| SCHEMBL22765174 | 0.79 | PRKCQ (1.00) | MAP3K11MAP3K9MAP3K10FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | PHARNEXT (FR) | 2021-02-02 | — | — | US | disclosed |
| US-10799499-B2 | Combinatorial therapies of neurological disorders | PHARNEXT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20190111054-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2019-04-18 | — | — | US | disclosed |
| EP-3411025-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | Pharnext (FR) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134280-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2017-08-10 | — | — | WO | disclosed |
| EP-3104850-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160354335-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2016-12-08 | — | — | US | disclosed |
| WO-2015121218-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2015-08-20 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | CPT1B, APOB, GABRB3 | MAP3K11 3111/4885MAP3K9 3870/4885MAP3K10 3423/4885 |
| US-20160354335-A1 | COMBINATION OF BACLOFEN, ACAMPROSATE AND MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | CPT1B, APOB, GABRB3 | MAP3K11 3123/4885MAP3K9 3949/4885MAP3K10 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.